Literature DB >> 8912374

Microdosimetry and radiocurability: modelling targeted therapy with beta-emitters.

A E Nahum1.   

Abstract

Tumour control probability (TCP) is a more relevant quantity than the dose distribution in the target volume for estimating the likely efficacy of any type of radiation therapy, be it external beam or targeted using radionuclides. This paper concentrates on a TCP modelling study, for tumour spheres of different radii assuming a uniform uptake of six different beta emitters (ranging from 67Cu to 90Y or 0.58 to 2.3 MeV in endpoint energy). The dose at varying radii, expressed as a fraction of the equilibrium dose, D beta (R)/Deq, was computed by numerical integration of the point-dose kernel over the sphere volume, and shows clearly the effect of electron disequilibrium for small radii and also at the edges of the spheres. These D beta(R)/Deq were converted into volume-dose distribution V(D) and thence into clonogenic cell numbers, n(D), from which the TCPs for spheres of different radii were computed, for different cumulated activities per unit mass, in megabecquerel hours per gram assuming a clonogenic cell density of 10(8) cm-3 and a tumour-cell radiosensitivity alpha of 1.0 Gy-1. Using V(D) rather than simply the mean dose decreases the TCP at both large and small tumour radii for a given number of megabecquerel hour per gram. Curves of iso-TCP go through a shallow minimum in megabecquerel hour per gram at a tumour radius approximately equal to the maximum beta-particle range. The fall in dose at small radii outweighs the reduction in cell number, making it improbable that micrometastases can be eliminated solely by beta-emitters targeted to the tumour cells. An explicit comparison with external-beam therapy for a fixed number of tumour cells divided into different numbers of spheres further emphasizes the difficulties caused by small tumours in beta-particle targeted therapy. Alternative strategies to overcome these limitations are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912374     DOI: 10.1088/0031-9155/41/10/008

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  4 in total

1.  A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.

Authors:  Robert F Hobbs; Sébastien Baechler; De-Xue Fu; Caroline Esaias; Martin G Pomper; Richard F Ambinder; George Sgouros
Journal:  Med Phys       Date:  2011-06       Impact factor: 4.071

2.  Defining the role for dosimetry and radiobiology in combination therapies.

Authors:  Manuel Bardiès; Glenn D Flux
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-01       Impact factor: 9.236

Review 3.  Preclinical animal research on therapy dosimetry with dual isotopes.

Authors:  Mark W Konijnenberg; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-01       Impact factor: 9.236

4.  Towards translation of 212Pb as a clinical therapeutic; getting the lead in!

Authors:  Kwon Yong; Martin W Brechbiel
Journal:  Dalton Trans       Date:  2011-03-04       Impact factor: 4.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.